Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)

Authors
Category Primary study
JournalJ Clin Oncol
Year 2008
This article has no abstract
Epistemonikos ID: ff3d40787f4ba8837e26852244bb2cc52da87bc1
First added on: Oct 15, 2018